Acute Myeloid Leukaemia

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

30.0 / 100K

11 drugs in development·5 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
olverembatinib	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 2(1)

Drug	Company
fludarabine	Sanofi (SNY)

Phase 1(5)

Drug	Company
fludarabine	Sanofi (SNYNF)
lisaftoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
olverembatinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
sar445419	Sanofi (SNY)
sar445419	Sanofi (SNYNF)

Phase 1/Phase 2(3)

Drug	Company
lisaftoclax	CHINA PHARMA HOLDINGS, INC. (CPHI)
reduced-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
standard-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Phase 2/Phase 3(1)

Drug	Company
liposomal annamycin injection in combination with cytarabine	Moleculin Biotech, Inc. (MBRX)

BioSniper tracks 11 drugs in development for Acute Myeloid Leukaemia across 5 companies.

There are 3 clinical trials targeting Acute Myeloid Leukaemia tracked by BioSniper.

The estimated prevalence of Acute Myeloid Leukaemia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.